Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed... see more

Recent & Breaking News (NDAQ:MRSN)

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates

GlobeNewswire November 2, 2020

Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

GlobeNewswire October 14, 2020

Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study

GlobeNewswire September 17, 2020

Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress

GlobeNewswire September 10, 2020

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 3, 2020

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 2, 2020

Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs

GlobeNewswire August 31, 2020

Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer

GlobeNewswire August 11, 2020

Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire August 7, 2020

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire August 4, 2020

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates

GlobeNewswire July 31, 2020

Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms at American Association for Cancer Research 2020 Virtual Annual Meeting

GlobeNewswire June 22, 2020

Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire June 2, 2020

Mersana Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire May 28, 2020

Mersana Therapeutics to Present at Jefferies Virtual Global Healthcare Conference

GlobeNewswire May 28, 2020

Mersana Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire May 28, 2020

Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study

GlobeNewswire May 27, 2020

Mersana Therapeutics to Present Two Posters at the American Association for Cancer Research 2020 Virtual Annual Meeting

GlobeNewswire May 15, 2020

Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose Escalation Study

GlobeNewswire May 14, 2020

Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at the American Society of Clinical Oncology 2020 Virtual Scientific Program

GlobeNewswire May 13, 2020